National Health (Pharmaceutical Benefits) Regulations (Amendment)

STATUTORY RULES

1968 No.

________

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1967.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following regulations under the National Health Act 1953-1967.

Dated this twenty-first day of March, 1968.

CASEY

Governor-General.

By His Excellency’s Command,

(SGD.) A. J. FORBES

Minister of State for Health.

________

Amendments of The National Health (Pharmaceutical Benefits) Regulations†

Commencement.

1. These Regulations shall come into operation on the first day of April, 1968.

Pharmaceutical benefits that may be prescribed only for specified persons, diseases, &c.

2. Regulation 14 of the National Health (Pharmaceutical Benefits) Regulations is amended by adding at the end thereof the following sub-regulation:—

“ (5.) Where two or more pharmaceutical benefits are specified in the second column of the Fifth Schedule in respect of an item in that Schedule, any purpose, condition or restriction specified in the third column of that Schedule in respect of that item applies to and in relation to each of those pharmaceutical benefits.”.

First Schedule.

3. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 10 and item 185.

Second Schedule.

4.—(1.) The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 22 and inserting in its stead the following item:—

“ 22	Chloramphenicol, B.P. ..	Chloramphenicol B.P. with Polymyxin B. Sulphate B.P.
		Chloramphenicol B.P. with Hydrocortisone Acetate B.P.”.

(2.) The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 65 and inserting in its stead the following item:—

“ 65	Hydrocortisone Acetate, B.P. ..	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
		Hydrocortisone Acetate B.P. with Gramicidin, Neomycin Sulphate B.P., Thonzonium Bromide and Thonzylamine Hydrochloride
		Hydrocortisone Acetate B.P. with Chloramphenicol B.P.”.

* Notified in the Commonwealth Gazette on 1968.

† Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; 1966, Nos. 80 and 144; and 1967, Nos. 67, 116 and 158.

13393/68—Price 20c 10/13.3.1968

Third Schedule.

5. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after item 32 the following item:—

“ 32a. Anti-Haemophilic Factor of Animal Origin ”;

(b) by omitting item 40;

“ 76a. Charcoal ”;

(d) by omitting item 125 and inserting in its stead the following item:—

“ 125. Doxycyline Hyclate ”;

(e) by inserting after item 147 the following item:—

“ 147a. Ferrous Fumarate ”;

(f) by inserting after item 149 the following item:—

“ 149a. Flufenamic Acid ”;

(g) by inserting after item 168 the following item:—

“ 168a. Guanacline ”;

(h) by omitting item 188;

(i) by omitting item 338 and inserting in its stead the following item:—

“ 338. Stone Fish Antivenene ”; and

(j) by inserting after item 375 the following item:—

“ 375a. Tolazamide ”.

Fifth Schedule.

6. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule inserted in its stead:—

FIFTH SCHEDULE

Regulation 14.

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcysteine...........	Fibrocystic Disease
2	(1) Acetylsalicylic Acid Tablets, B.P.	Any disease or condition in a pensioner
	(2) Soluble Acetylsalicylic Acid Tablets B.P.
	(3) Acetylsalicylic Acid with Paracetamol and Caffeine Tablets
	(4) Acetylsalicylic Acid with Codeine Phosphate and Pentobarbitone Sodium
3	Acrylic Resin............	Ileostomy or colostomy conditions
4	Aldosterone.............	With the written authority of the Director-General, treatment of an acute crisis in—
		Addison’s disease
		Salt-losing congenital adrenal hypoplasia
5	Allopurinol.............	Chronic gout not responding to other pharmaceutical benefits
		Gout associated with renal failure
6	(1) Aminocaproic Acid	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Amino Acids

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
7	(1) Amitriptyline Hydrochloride	Any disease or condition in a pensioner
	(2) Amitriptyline Tablets, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride
8	Amphetamine Sulphate Tablets, B.P.	Any disease or condition in a pensioner
9	Amphotericin B...............	Systemic fungal infection
10	(1) Ampicillin Capsules, B.P.......	With the written authority of the Director-General—
	(2) Ampicillin Injections, Tablets and Suspension	Gram-negative infections in pregnant women
	(2) Ampicillin Injections, Tablets and Suspension	Infections, in children under the age of five years, in which penicillin and sulphonamides are not effective
		Infections where positive bacteriological evidence confirms that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent
11	Aneurine Hydrochloride Tablets B.P.	Any disease or condition in a pensioner
12	Angiotensin Amide.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
13	Ascorbic Acid Tablets, B.P........	Any disease or condition in a pensioner
14	(1) Azathioprine...............	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Beclamide................
15	Benzoin Compound Tincture, B.P.C.	Ileostomy or colostomy conditions
16	Betamethasone Tablets..........	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
17	Betamethasone Acetate and Betamethasone Alcohol Injection	Intra-articular use
18	Betamethasone Sodium Phosphate Injection, B.P.	Intra-articular use
19	Busulphan Tablets, B.P..........	Treatment in neoplastic disease
20	(1) Calciferol Tablets, B.P........	Any disease or condition in a pensioner
	(2) Calciferol, B.P..............	With the written authority of the Director-General—
		Hypoparathyroidism
		Chronic hypoparathyroid tetany
		Vitamin D-resistant rickets
21	Calcium Aminosalicylate ..	Tuberculosis
22	Calcium Gluconogalactogluconate Effervescent Tablets	Hypoparathyroidism
23	Carbamazepine...............	Epilepsy
		Trigeminal neuralgia
24	(1) Carbenoxolone Sodium.......	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Cephaloridine..............
25	Charcoal Tablets..............	Ileostomy or colostomy conditions
26	Chlorambucil Tablets, B.P	Treatment in neoplastic disease
27	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
28	Chloramphenicol Capsules, B.P.	Bacterial meningitis
		Haemophilus influenzae infections
		Intra-ocular infections
		Rickettsial infections
		Salmonella septicaemia
		Typhoid and paratyphoid
		Other serious infections sensitive only to Chloramphenicol
29	(1) Chloramphenicol Injections.....	A disease or condition specified in this column in relation to Chloramphenicol Capsules
	(2) Chloramphenicol Tablets
	(3) Chloramphenicol Oral Suspension
30	Chlorotrianisene Tablets..........	Carcinoma of the prostate
31	(1) Chlorpromazine Hydrochloride B.P.	Any disease or condition in a pensioner
	(1) Chlorpromazine Hydrochloride B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Chlorpromazine Injection B.P.
	(3) Chlorpromazine Tablets B.P.	With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride
32	Chlortetracycline Capsules B.P.....	Brucellosis
		Herpes zoster ophthalmicus
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Psittacosis
		Rickettsial infections
		Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
33	Chlortetracycline Hydrochloride Granules	A disease or condition specified in this column in relation to Chlortetracycline Capsules
34	(1) Cloxacillin Sodium, B.P. ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Cloxacillin Capsules, B.P.
35	(1) Codiene Phosphate with Acetylsalicylic Acid Soluble Tablets	Any disease or condition in a pensioner
	(2) Codeine Phosphate with Acetylsalicylic Acid Tablets
	(3) Codeine Phosphate with Acetylsalicylic Acid and Paracetamol Soluble Tablets
	(4) Codeine Phosphate with Acetylsalicylic Acid, Paracetamol and Caffeine Tablets

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
36	Cod Liver Oil Emulsion.........	Any disease or condition in a child under the age of twelve years or in a pensioner
37	Colistin Sulphomethate Injection, B.P.	Pyocyaneus infection and Gram-negative infections where no other drug is effective
38	(1) Corticotrophin Injection, B.P.	With the written authority of the Director-General—
	(2) Corticotrophin Gelatin Injection, B.P.	Hypsarrhythmia
	(2) Corticotrophin Gelatin Injection, B.P.	Salaam convulsions
	(3) Corticotrophin Zinc Hydroxide Injection, B.P.	The prevention of side effects of corticosteroid therapy
		A disease or condition specified in this column in relation to Cortisone Injection with the exception of—
		Adrenalectomy, total
		Benign intracranial hypertension
		Encephalitis
		Meningitis
		Oedema of the spinal cord following trauma or infection
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
39	Cortisone Injection, B.P.........	With the written authority of the Director-General—
		Acute exophthalmic ophthalmoplegia
		Acute heart block complicating myocardial infarction
		Anaemia, acquired haemolytic
		Addison’s disease
		Adrenocortical hypoplasia
		Adrenalectomy, total
		Adrenogenital syndrome
		Agranulocytosis
		Behcet’s syndrome
		Benign intracranial hypertension
		Cerebral tumours and cerebral oedema
		Cranial arteritis
		Cushing’s syndrome, including hyperadrenocorticalism
		Dermatitis, acute exfoliative
		Dermatomyositis
		Encephalitis
		Encephalomyelitis
		Encephalomyelitis, acute disseminated
		Giant cell thyroiditis proven by biopsy
		Guillain-Barré syndrome
		Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
		Hansen’s disease
		Hepatitis, progressive or continuing, proven by biopsy or biochemistry
		Hodgkin’s disease
		Idiopathic hypercalcaemia
		Inflammatory conditions of the uveal tract and retina
		Interstitial Keratitis due to syphilis or vernal conjunctivitis
		Keratoplasty
		Leucine-sensitive hypoglycaemia
		Leukaemia
		Lymphosarcoma and follicular lymphoma
		Meningitis
		Metastatic breast cancer
		Mycosis fungoides
		Nephrosis or nephrotic syndrome

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
39	Cortisone Injection, B.P.—continued	Neuromyelitis optica
	Cortisone Injection, B.P.—continued	Oedema of the spinal cord following trauma or infection
		Optic neuritis following removal of tumor of the brain
		Panhypopituitarism
		Pemphigus
		Periateritis nodosa
		Progressive transverse myelitis
		Pseudohermaphroditism
		Pulmonary eosinophilia
		Purpura, Henoch’s
		Purpura, thrombocytopenic
		Red cell aplasia
		Regional iletis (Crohn’s disease)
		Reticulum cell sarcoma
		Rheumatic carditis, acute
		Sarcoidosis
		Scleroderma
		Severe reactions of the skin and mucosa following X-ray therapy
		Splenic neutropenia
		Status asthmaticus
		Steroid therapy prior to operation in patients under steroid therapy
		Stevens-Johnson syndrome
		Still’s disease in a child under the age of sixteen years
		Sneddon and Wilkinson’s sub-corneal pustular dermatosis
		Sympathetic ophthalmitis
		Systemic lupus erythematosus
		Temporal arteritis
		Treatment of malignancy in conjunction with radiotherapy or chemotherapy
		Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
		Type II Nephritis
		Ulcerative colitis proven by sigmoidscopy or radiological report
40	Cortisone Tablets, B.P..........	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection
41	Cyanocobalamin Injection, B.P.	Established megalocytic anaemia
		Neuroblastoma
		Sub-acute combined degeneration of the cord
		Treatment in post-gastrectomy
42	Cymogran..................	With the written authority of the Director-General, phenylketonuria
41	(1) Cycloserine Tablets, B.P.......	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Cycloserine Capsules, B.P.....
42	(1) Demethylchlortetracycline Capsules, B.P.	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
	(2) Demethylchlortetracycline Hydrochloride Oral Paediatric Drops and Oral Suspension
43	Demethylchlortetracycline Hydrochloride with Nystatin	Any disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin
44	Deodorant Detergent Solution (Terric with Spearmint Oil and Cetrimide)	Ileotomy or colostomy conditions

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
45	(1) Deoxycortone Aqueous Injections	Addison’s disease
	(1) Deoxycortone Aqueous Injections	Adrenalectomy, total
	(2) Deoxycortone Acetate Injec-jection, B.P.
	(3) Deoxycortone Trimethylacetate Injection, B.P.
	(4) Deoxycortone Acetate Implants, B.P.
	(5) Deoxycortone Acetate Tablets
46	Desferrioxamine..............	Any disease or condition in a patient receiving treatment in or at an approved hospital
47	Dexamethasone Tablets, B.P......	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
48	Dexamethasone Sodium Phosphate Injections	Intra-articular use
	Dexamethasone Sodium Phosphate Injections	Cerebral oedema
49	Dexamphetamine Tablets, B.P.....	Any disease or condition in a pensioner
50	(1) Dextromoramide Tablets......	Treatment in neoplastic disease
	(2) Dextromoramide Injection
51	Diazepam Injection, Syrup and 10 mg. tablet	Epilepsy
	Diazepam Injection, Syrup and 10 mg. tablet	Upper motor neurone lesion
52	Diazepam Tablets 2 mg. and 5 mg.	Epilepsy
		Upper motor neurone lesion
		Treatment in multiple sclerosis
53	Dienoestrol Cream.............	Any disease or condition in a pensioner
54	Dienoestrol Tablets, B.P.........	Carcinoma of the prostate
		Mammary carcinoma
		Any disease or condition in a pensioner
55	Dihydrotachysterol.............	Parathyroid deficiency
56	Diloxanide Furoate Tablets, B.P.	Amoebic dysentery
57	Dimethicone.................	Ileostomy or colostomy conditions
58	Disodium Stilboestrol Diphosphate	Carcinoma of the prostate
59	Ditophal....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
60	Doxycycline Hyclate...........	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
61	Erythromycin................	Brucellosis
		Intestinal amoebiasis
		Leptospirosis
		Lymphogranuloma venereum
		Mycoplasma pneumoniae (Eaton’s Agent)
		Psittacosis
		Rickettsial infections
		Staphylococcal septicaemia or staphylococcal pneumonia
		Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
		Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
62	Ethinyloestradiol Tablets, B.P.....	Any disease or condition in a pensioner
		Hereditary telangiectasis
		Pre-menopausal castration syndrome
		Turner’s syndrome
63	Ethionamide ................	Tuberculosis
64	Ethisterone Tablets, B.P.........	Turner’s syndrome

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
65	Ethyloestrenol...............	With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis
		Intermittent use for patients on long term treatment with corticosteroids
66	Fludrocortisone Tablets, B.P......	Addison’s disease
		Adrenocortical hypoplasia
		Total adrenalectomy
67	Flufenamic Acid..............	Any disease or condition in a patient receiving treatment in or at an approved hospital
68	Fluorouracil Sodium...........	Treatment in neoplastic disease
69	Fluoxymesterone Tablets, B.P.....	Castration syndrome (male)
		Mammary carcinoma
		With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
70	(1) Fluphenazine Oenanthate......	Any disease or condition in a pensioner
	(2) Fluphenazine Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
		With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		Huntington’s chorea
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
		Fluphenazine Oenanthate
		Fluphenazine Hydrochloride
71	(1) Folic Acid Injection.........	Macrocytic anaemia
	(2) Folic Acid Tablets, B.P.......	Sprue or the sprue-like syndrome
72	Folinic Acid................	Any disease or condition in a patient receiving treatment in or at an approved hospital
73	Framycetin Sulphate Tablets......	Bowel sterilization preparatory to major surgery
74	Fusidic Acid (Sodium Salt or Diethanolamine Salt)	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic
75	Galactomin Formula No. 11......	With the written authority of the Director-General—
		Galactosaemia
		Conditions needing an extreme restriction of lactose in the patient’s diet, in children under the age of four years
76	Galactomin Formula No. 19......	With the written authority of the Director-General—
		Glucose-galactose malabsorption
77	Goats Milk, dehydrated.........	With the written authority of the Director-General, cows milk allergy in children under the age of four years
78	Griseofulvin Tablets, B.P........	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
79	Guanacline Tablets.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
80	Halibut Liver Oil Capsules........	Any disease or condition in a pensioner
81	Hetacillin Capsules.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
82	(1) Hexachlorophane with Entsufon	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Hexachlorophane with Lissapol
	(3) Hexachlorophane in Soap solution
83	Hydrocortisone Injection.........	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection
84	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
85	Hydrocortisone Sodium Succinate Injection	Acute adrenal failure due to medical or surgical crisis
	Hydrocortisone Sodium Succinate Injection	Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
		Stevens-Johnson syndrome
86	Hydroxocobalmin Injection, B.P.	Established megalocytic anaemia
		Neuroblastoma
		Sub-acute combined degeneration of the cord
		Treatment in post-gastrectomy
87	Hydroxyprogesterone...........	Endometrial carcinoma
		Habitual abortion
		Progesterone deficiency proven by hormonal assay of lateral wall smear
88	Idoxuridine..................	Infections caused by Herpes Simplex Virus
89	(1) Imipramine Tablets, B.P.	Any disease or condition in a pensioner
	(2) Imipramine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride
90	Indomethacin Capsule	Rheumatoid arthritis or osteoarthritis not responding to salicylates
		Acute attacks of gout
		Ankylosing spondylitis
		Psoriatic arthritis
		Reiter’s syndrome
91	Isoniazid Tablets, B.P.	Tuberculosis
92	Kanamycin Sulphate Capsules, Injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic
93	Kitasamycin.................	Any disease or condition in a patient receiving treatment in or at an approved hospital
94	Levorphanol Tartrate............	Obstetrical use
		Severe intractable pain

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
95	Lincomycin Hydrochloride.......	Osteomyelitis
		Pneumococcal Meningitis
		Staphylococcal infections where these cannot be safely and effectively treated with Penicillin
96	Liothyronine Tablets, B.P........	Myxoedema
		Myxoedema coma
97	Lipopancreatin...............	Fibrocystic disease
		Pancreatico-duodenectomy
		Pancreatic steatorrhea
98	Lofenalac...................	With the written authority of the Director-General, phenylketonuria
99	Medroxyprogesterone Acetate Tablets 2.5 mg. and 10 mg.	Endometrial carcinoma
100	Medroxyprogesterone Acetate Injections and Oral Tablets 100 mg.	Adenocarcinoma of the body of the uterus
		Clear cell carcinoma of the kidney
		Endometrial carcinoma
		Progesterone deficiency proven by hormonal assay of lateral wall smear
101	Melphalan..................	Treatment in neoplastic disease
102	Mercaptopurine Tablets, B.P......	Allergic angiitis
		Treatment in neoplastic disease
		Lupus erythematosus
		Nephrosis or Nephrotic syndrome
		Periarteritis
103	Mestanolone.................	Mammary carcinoma
		With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteriods
104	Methacycline................	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
105	(1) Methandienone Tablets, B.P.	With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis
	(2) Methenolone Acetate.........
		Intermittent use for patients on long-term treatment with corticosteriods
106	(1) Methicillin Sodium..........	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Methicillin Injection, B.P......
107	Methotraxate Tablets...........	Treatment in neoplastic disease
108	Methotrexate Injections..........	Any disease or condition in a patient receiving treatment in or at an approved hospital
109	(1) Methylamphetamine Injection, B.P.	Any disease or condition in a pensioner
	(2) Methylamphetamine Tablets, B.P.
110	Metyrapone.................	Any disease or condition in a patient receiving treatment in or at an approved hospital
111	Minafen....................	With the written authority of the Director-General, phenylketonuria
112	Morphine Sulphate, B.P. with Tacrine Tablets	Severe intractable pain
113	Mustine Hydrochloride Injection	Treatment in neoplastic disease
114	Nalidixic Acid................	With the written authority of the Director-General, urinary tract infections
115	Nandrolone Phenylpropionate Injection, B.P.	With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis

Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
116	Nandrolone Decanoate..........	Mammary carcinoma
		With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteriods
117	Neomycin Sulphate Powder.......	With the written authority of the Director-General, intermittent use by inhalation in fibrocystic disease
118	Neomycin Sulphate, B.P. with Gramicidin, Thonzomium Bromide, Thonzylamine Hydrochloride and Hydrocortisone Acetate, B.P.	Any disease or condition in a pensioner
119	Neomycin Tablets, B.P .........	Bowel sterilization preparatory to major surgery
		Portal-systematic encephalopathy
120	Nicotinic Acid Tablets, B.P.......	Any disease or condition in a pensioner
121	(1) Nitrofurantoin Tablets, B.P.....	Urinary tract infections
	(2) Nitrofurantoin Oral Suspension
122	Nitromin...................	Treatment in neoplastic disease
123	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a pensioner
	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Nortriptyline Tablets, B.P......
	(3) Nortriptyline Capsules, B.P.....	With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride
124	Nutramigen.................	With the written authority of the Director-General—
		Cows milk allergy in children under the age of four years
		Galactosaemia
		Lactose intolerance
		Fibrocystic disease of the pancreas
125	Nystatin Tablets, B.P...........	Monilia infections
126	(1) Orciprenaline Sulphate Injection	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Orciprenaline Sulphate Solution for Inhalation
127	Oxycodone Pectinate...........	Treatment in neoplastic disease
128	Oxymesterone................	With the written authority of the Director-General, intermittent use for corticosteriod-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteriods
129	(1) Oxytetracycline Hydrochloride Capsules	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
	(2) Oxytetracycline Tablets, B.P.
	(3) Oxytetracycline Injections
	(4) Calcium di-Oxytetracycline Oral Suspension
	(5) Calcium di-Oxytetracycline Paediatric Drops

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
130	Oxytetracycline Hydrochloride with a buffering agent and Nystatin	Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
		A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
131	(1) Pancreatin, B.P. .. ..	Fibrocystic disease
	(2) Pancreatin Enzyme U.S.N.F. XI	Pancreatico-duodenectomy
	(2) Pancreatin Enzyme U.S.N.F. XI	Pancreatic steatorrhoea
132	Para-Aminosalicylic Acid ..	Tuberculosis
133	(1) Paracetamol Suspension ..	Any disease or condition in a pensioner
	(2) Paracetamol Tablets, B.P.
134	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
135	Paramethasone Acetate ..	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection
136	(1) Paraffin Liquid Emulsion ..	Any disease or condition in a pensioner
	(2) Paraffin Liquid Emulsion with Phenolphthalein
137	Pargyline Hydrochloride ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
138	Penicillamine .. ..	With the written authority of the Director-General—
		Cystinisis
		Cystinuria with calculus formation
		Treatment of cold agglutinin haemoglobinuria
		Acute heavy metal intoxication
		Wilson’s Disease (hepatolenticular degeneration)
139	(1) Penicillin Benzathine Tablets and Capsules	Prevention of recurrent streptococcal infections, including rheumatic fever
	(2) Penicillin Benzyl Tablets, B.P.
	(3) Penicillin Benzyl Capsules
140	Benzylpenicillin Injection 5,000,000 units and 10,000,000 units	Bacterial endocarditis or septicaemia
141	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to Streptococcus faecalis or Streptococcus viridans
	(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
142	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetrical use
143	(1) Phenylbutazone Tablets, B.P.	Rheumatoid arthritis or osteoarthritis not responding to salicylates
	(2) Phenylbutazone Capsules
		Acute attacks of gout
		Ankylosing spondylitis
		Psoriatic arthritis
		Reiter’s syndrome
144	Phytomenadione Injection, B.P. ..	Antidote to anticoagulants
145	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
146	Polymyxin B. Sulphate Powder ..	With the written authority of the Director-General—
		Intermittent use by inhalation in fibrocystic disease
147	Polyoestradiol Phosphate ..	Carcinoma of the prostate
148	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General—
		Ulcerative colitis proven by sigmoidoscopy or radiological report
		Proctitis proven by sigmoidoscopy

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
149	Prednisolone Tablets, B.P........	With the written authority of the Director-General—
		Cerebral oedema; Cerebral tumors; Acute exophthalmic ophthalmoplegia; Interstitial keratitis due to syphilis or vernal conjunctivitis; Malignancy treatment in conjunction with radiotherapy or chemotherapy; Acute heart block complicating myocardial infarction; Benign intracranial hypertension; Encephalitis; Malignant exophthalmos; Meningitis; Nodular nonsuppurative panniculitis (Christian-Weber disease); Oedema of the spinal cord following trauma or infection; A disease or condition specified in this column in relation to Cortisone Injection except total adrenalectomy or Addison’s disease or andrenocortical hypoplasia
150	Prednisolone Methyl Acetate Injections	Intra-articular use
	Prednisolone Methyl Acetate Injections	Retrobulbar injection in posterior uveitis
151	(1) Prednisolone Acetate Injection	Intra-articular use
	(2) Prednisolone Tertiary Butyl Acetate Injections
	(3) Prednisolone Trimethylacetate Injections
152	(1) Methylprednisolone Tablets, B.P.	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
	(2) Methylprednisolone Capsules
153	Prednisolone Sodium Hemisuccinate	Acute adrenal failure due to medical or surgical crisis
	Prednisolone Sodium Hemisuccinate	Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
		Stevens-Johnson syndrome
154	Prednisone Tablets, B.P.........	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
155	Procarbazine Hydrochloride......	Treatment in neoplastic disease
156	Progesterone................	Habitual abortion
		Progesterone deficiency proven by hormonal assay of lateral wall smear
157	(1) Propranolol Hydrochloride.....	Any disease or condition in a patient receiving treatment in or at an approved hospital
	(2) Pyrazinamide
158	(1) Pyridostigmine Injection, B.P.	Myasthenia gravis
	(2) Pyridostigmine Tablets, B.P.
159	Pyridoxine Hydrochloride Tablets	Peripheral neuritis due to isoniazid therapy
		Radiation sickness
160	Pyrimethamine Tablets.........	Treatment of toxoplasmosis
161	(1) Quinine Bisulphate Tablets, B.P.	Dystrophia myotonica
	(1) Quinine Bisulphate Tablets, B.P.	Malaria
	(2) Quinine Dihydrochloride Tablets	Myotonia atrophica
	(2) Quinine Dihydrochloride Tablets	Myotonia congenita
	(3) Quinine Hydrochloride Tablets	Any disease or condition in a pensioner
	(4) Quinine Sulphate Tablets, B.P.
162	(1) Riboflavine Tablets.........	Any disease or condition in a pensioner
	(2) Senna Fruit Extract (Standardised)
163	Sobee.....................	With the written authority of the Director-General—
		Galactosaemia
		Homocystinuria
		Lactose intolerance
		Milk allergy in children under the age of four years

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
164	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
	(2) Sodium Aminosalicylate Injection
	(3) Sodium Aminosalicylate Cachets
	(4) Sodium Aminosalicylate Granules
	(5) Sodium Aminosalicylate with Isoniazid, B.P.
165	Sodium Folate...............	Macrocytic anaemia
		Sprue or the sprue-like syndrome
166	Spiramycin..................	Serologically proven active toxoplasmosis
		Staphylococcal septicaemia or staphyloccocal pneumonia
		Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
167	Spironolactone Tablets, B.P.......	With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate
		Myasthenia Gravis
168	Stanolone...................	Mammary carcinoma
		With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
169	Stanozolol..................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
		Intermittent use for patients on long-term treatment with corticosteroids
170	(1) Stilboestrol Injection.........	Carcinoma of the prostate
	(2) Stilboestrol Tablets, B.P.......	Mammary carcinoma
		Any disease or condition in a pensioner
		Hereditary Telengiectasis
171	Streptomycin Sulphate Injections	Bacillary dysentery that is resistant to the Sulphonamides
		Brucellosis
		Chancroid
		Endocarditis due to Streptococcus faecalis or Streptococcus viridans
		Friedlander bacillus infections
		Haemophilus influenzae infections
		Plague
		Pseudomonas pyocyanea infections
		Rat-bite fever (Steptobacillus moniliformis)
		Salmonella infections
		Surgical conditions of the bowel (pre-operative and post-operative)
		Surgical conditions of the thoracic organs
		Tuberculosis
		Tularaemia
		Urinary tract infections that are resistant to the Sulphonamides
172	Sulphasalazine ...............	Ulcerative colitis
173	Sulphomyxin Sodium...........	Any disease or condition in a patient receiving treatment in or at an approved hospital
174	Sultiame...................	For use where other anticonvulsants have failed
175	(1) Surgical Cement............	Ileostomy or colostomy conditions
	(2) Surgical Cement Solvent

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
176	(1) Sustanon.................	Castration syndrome (male)
	(2) Testosterone Implants, B.P.....	Klinfelter Reifenstein Albright syndrome
	(3) Testosterone Oenanthate.......	Mammary carcinoma
	(4) Testosterone Proprionate Injection, B.P.
	(5) Methyltestosterone Tablets, B.P.
	(6) Methyltestosterone, B.P.
177	Tetanus Antitoxin, B.P. (Bovine)	Patients known to be sensitive to horse serum
178	Tetanus Immune Globulin (Human)	With the written authority of the Director-General, where patients are known to be sensitive to horse scrum and cattle serum
179	Tetracosactide................	Any disease or condition in a patient receiving treatment in or at an approved hospital
180	(1) Tetracycline Capsules, B.P.....	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
	(2) Tetracycline Tablets, B.P......
	(3) Tetracycline Injections........
	(4) Rolitetracycline
	(5) Tetracycline Hydrochloride Granules, Paediatric Drops and Syrup
	(6) Tetracycline with a buffering agent
181	(1) Tetracycline with a buffering agent and Amphotercin B	A disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin
	(2) Tetracycline with a buffering agent and Nystatin
182	(1) Thiambutosine Tablets, B.P.	Hansen’s disease
	(2) Thiambutosine Injection
183	Thiethylperazine Tablets and Suppositories	Radiation sickness
184	(1) Thioridazine Tablets, B.P......	Any disease or condition in a pensioner
	(2) Thioridazine	Any disease or condition in a patient receiving treatment in or at an approved hospital
		With the written authority of the Director-General, Late-stage malignancy
		Radiation sickness
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
		Thioridazine
		Thioridazine Hydrochloride
185	Thyrotrophin.................	Any disease or condition in a patient receiving treatment in or at an approved hospital
186	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions
187	Trasylol....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
188	Tretamine...................	Treatment in neoplastic disease

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
189	(1) Trifluoperazine Tablets, B.P	Any disease or condition in a pensioner
	(2)Trifluoperazine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
		With the written authority of the Director-General—
		Late-stage malignancy
		Radiation sickness
		With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
		The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride
190	Triglyde....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
191	Trimetaphan Injection, B.P.......	Hypotensive for anaesthesia
192	Vadrine	Any disease or condition in a patient receiving treatment in or at an approved hospital
193	Vasopressin Nasal Spray.........	Diabetes insipidus
194	Velactin....................	With the written authority of the Director-General—
		Galactosaemia
		Homocystinuria
		Lactose intolerance
		Milk allergy in children under the age of four years
195	(1) Vinblastine Sulphate.........	Treatment in neoplastic disease
	(2) Vincristine Sulphate
196	(1) Viomycin Sulphate ..........	Tuberculosis
	(2) Viomycin Sulphate Injection, B.P.
197	Vitamin A with Aneurine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D	Any disease or condition in a pensioner
198	Neomycin Sulphate Powder.......	With the written authority of the Director-General—
		Intermittent use by inhalation in fibrocystic disease

______________________

By Authority: A.J. ARTHUR Commonwealth Government Printer Canberra

Administered by Department of Health, Disability and Ageing

Interactions

Legislation content

Interactions

Authorises

All Versions